Cupid Limited (NSE: CUPID) eyes Saudi Arabian manufacturing after record Q2, Rs 335cr topline guidance intact

Cupid Limited (NSE: CUPID, BSE: 530843) has received in-principle board approval to set up its first overseas manufacturing facility in Saudi Arabia, aligning with its strategy to deepen presence in the Gulf Cooperation Council region and improve supply chain resilience for its expanding FMCG and diagnostics portfolio. This announcement comes on the heels of the company’s strongest-ever quarterly performance in Q2 FY26, where it reaffirmed its full-year revenue guidance of ₹335 crore and net profit outlook of over ₹100 crore.

As of market close on 29 December 2025, shares of Cupid Limited rose 1.56 percent to ₹487.00, reflecting positive investor sentiment following the dual update on international expansion and earnings strength. The stock traded in a narrow band between ₹480.70 and ₹493.25, with the volume-weighted average price (VWAP) at ₹487.25, marginally higher than the closing price of ₹486.60. The surge adds to a broader trend of institutional optimism around mid-cap exporters with earnings visibility and certification-led entry into regulated markets.

Why Cupid Limited’s Saudi plant marks a turning point in its global manufacturing strategy

Cupid Limited’s move to establish a manufacturing facility in Saudi Arabia is more than a geographic expansion. It signals a deliberate shift to create localized capacity closer to procurement-heavy international markets. The company cited several benefits for this transition, including faster delivery timelines, enhanced product availability, and increased competitiveness in regional tenders. As the first overseas production base for the company, the Saudi plant is expected to serve not only the Kingdom of Saudi Arabia but the broader Gulf Cooperation Council bloc.

Funding for the facility will come from internal accruals, demonstrating the company’s strong balance sheet and self-funded expansion model. The move is also timed with broader macroeconomic shifts, as governments in the Middle East seek to onshore more of their essential health and wellness supply chains. Cupid Limited’s early-mover decision could help it consolidate share in donor-funded procurement programs, particularly in the diagnostics and condom export verticals where local manufacturing offers both pricing and compliance advantages.

What drove Cupid Limited’s record earnings performance in Q2 FY26

In Q2 FY26, Cupid Limited reported a total income of ₹90.23 crore, a 91 percent year-on-year growth compared to ₹47.28 crore in Q2 FY25. Operating income rose to ₹84.45 crore, and EBITDA jumped 176 percent to ₹28.41 crore, with the EBITDA margin expanding from 25 percent to 34 percent. Net profit came in at ₹24.12 crore, representing a 140 percent increase from the previous year. Net profit margin also improved to 29 percent.

The surge was supported by a well-executed performance across both domestic and export segments. In India, the company gained ground in multiple FMCG subcategories, including deodorants, pregnancy detection kits, face wash, almond oil, and petroleum jelly. Distribution scale improved across modern trade, general trade, and e-commerce channels, while product-level brand activation enhanced consumer pull and repeat purchase rates.

On the export front, the company benefitted from stronger institutional allocations in priority markets across Africa, Southeast Asia, and the Middle East. Its CE-certified in-vitro diagnostics kits and existing WHO/UNFPA pre-qualification for both male and female condoms ensured high eligibility in donor-led tenders. Combined with capacity debottlenecking and disciplined procurement, this execution strength significantly boosted operational leverage.

How Saudi expansion aligns with broader certification and capacity strategies

The Saudi plant announcement is strategically aligned with other ongoing expansion and certification initiatives. Cupid Limited recently acquired land in Palava, Maharashtra, where it is scaling up its domestic manufacturing capacity to 2.5 times current levels. The Palava facility, expected to be commissioned by FY27, will boost annual production capacity by approximately 770 million male condoms and 75 million female condoms. Once both Palava and Saudi units are fully operational, the company will be positioned to support both domestic retail and global institutional demand simultaneously.

In diagnostics, Cupid is targeting CE-marked expansion across Europe, Africa, and Asia, with WHO prequalification for malaria test kits planned in FY27. Meanwhile, the company is progressing a next-generation Ring Female Condom through UNFPA/WHO prequalification channels. These regulatory milestones are critical because they unlock multi-year procurement eligibility, which directly feeds into volume visibility and margin stability.

The expansion is not just capacity-led but is also being enabled by smarter procurement practices that reduce bottlenecks and enhance productivity per manufacturing line. This dual-pronged approach of expanding scale while tightening execution discipline is expected to continue driving EBITDA margin improvements through FY27.

What does the market’s reaction signal about Cupid’s investment thesis?

The stock’s move to ₹487.00 on 29 December 2025, up 1.56 percent intraday, highlights investor confidence in Cupid Limited’s execution capability and future earnings potential. While the scrip is part of the LT ASM-1 framework and carries a high trailing price-to-earnings ratio, recent performance and forward visibility are supporting valuation. Institutional sentiment appears to be shifting in favor of mid-cap exporters with prequalified certifications, well-hedged international presence, and FMCG product traction.

Cupid’s consistent communication of earnings guidance, coupled with timely expansion announcements, is reinforcing credibility among long-term investors. Market watchers will now be keenly observing Q3 and Q4 execution trends to validate the ₹335 crore topline and ₹100 crore net profit trajectory.

Given that the company is still relatively under-covered in the public market ecosystem, further delivery on certification milestones, Saudi execution, and FMCG product expansion could potentially trigger re-rating catalysts.

How Cupid Limited is positioning for FY27 and beyond in the FMCG and diagnostics space

Cupid Limited’s current strategic posture reflects a company shifting from niche export play to mainstream mid-cap FMCG and diagnostics contender. Its product diversification, ranging from condoms and lubricants to diagnostics kits, fragrances, and wellness products, is designed to capture both retail and institutional demand. With regulatory approvals as the foundation and dual-plant manufacturing scale as the operational core, Cupid is laying the groundwork for high-certainty revenue streams in B2B and higher-margin growth in B2C.

The company’s Saudi investment also reflects a strategic read on shifting procurement dynamics, where local presence is becoming a bidding advantage in the global South. By positioning early, Cupid can not only tap regional growth but also hedge against future policy-driven trade frictions.

If it can deliver on its Palava and Saudi commissioning timelines, execute on its diagnostics certification roadmap, and continue expanding FMCG reach in India and abroad, Cupid Limited could move into a new valuation bracket by FY27.

Key takeaways on Cupid Limited’s record quarter and Saudi expansion strategy

• Cupid Limited has received board approval to set up its first international FMCG manufacturing facility in Saudi Arabia, enhancing its supply chain strength in the GCC region.

• The expansion aligns with ongoing scale-up in Palava and positions the company for faster delivery, local compliance benefits, and eligibility in Gulf public tenders.

• Q2 FY26 marked the highest quarterly performance in the company’s history, with net profit up 140 percent year-on-year and EBITDA margin reaching 34 percent.

• India FMCG sales improved across multiple product categories, while export momentum remained strong due to regulatory qualifications and institutional demand.

• The Saudi facility will be funded through internal accruals and follows a capital-efficient strategy of manufacturing proximity and regulatory-led market entry.

• Investor sentiment is turning increasingly positive as the stock closed at ₹487.00 on 29 December 2025, reflecting confidence in execution and earnings visibility.

• Cupid Limited remains on track to achieve its ₹335 crore topline and ₹100 crore net profit guidance for FY26, with potential upside in Q4.

• Certification milestones in diagnostics and product innovation in female health are expected to drive the next growth phase through FY27.